Abstract
control key risk factors such as tobacco smoking, air pollution, low income, malnutrition and difficulties to access health care facilities. 2 COPD mortality rates range between 15%-54%, and are higher in hospitalized patients with acute exacerbation of the disease (AECOPD). 3 The lowest COPD mortality rates are currently observed in Japan, Europe and other western countries, where the most advanced diagnostic and treatment options are available, and active research is ongoing. 4 The blood neutrophil to lymphocyte ratio (NLR), a simple, widely available, low cost index obtained from complete blood counts, has been recently proposed as a predictor of the onset, progression, and prognosis of several chronic inflammatory diseases 5 and cancer. [6] [7] [8] The rationale behind the NLR involves disease-related modifications of the most representative cell populations of inflammation. In COPD, the number of neutrophils is increased in the bronchoalveolar lavage, sputum, bronchial glands and airway smooth muscle. The distal lung is also involved by neutrophil-mediated inflammatory changes. Neutrophils can release oxidants and proteinases that favour a progressive destruction of the pulmonary parenchyma and stimulate the secretion of mucus which determines airflow limitation. 9 Furthermore, external agents such as tobacco smoking stimulate the secretion of interleukin-8 and interferon-α, which, in turn, contribute to neutrophilic inflammation, immunosuppression and recurrent exacerbations of the disease. 10 Several studies have investigated whether the NLR differs between health subjects and patients with stable COPD, and between patients with stable COPD and those experiencing exacerbations. We conducted a systematic review and meta-analysis of published studies in order to estimate the effect size of these differences.
| MATERIALS AND METHODS

| Eligibility criteria
Human studies were considered eligible if they met the following criteria: (a) assessment of blood neutrophil-to-lymphocyte ratio during the stable phase of disease for COPD or at the time of admission for AECOPD, (b) compared subjects with or without COPD or stable COPD with AECOPD (case-control design), (c) COPD diagnosed according to the criteria of the Global Initiative for Chronic Obstructive Lung Disease (GOLD), 11 (d) English language, (e) full-text publications.
| Search strategy and study selection
A comprehensive literature search was conducted in Pubmed, Web of Science and Scopus databases, from inception to September 2017, using the following terms:
"NLR ratio" OR "neutrophils-to-lymphocyte ratio" AND "COPD" OR "chronic obstructive pulmonary disease". Abstracts were independently screened by two investigators. If relevant, full articles were retrieved. References, in these articles, citing relevant reviews or original studies were also accessed to identify additional eligible studies. Any disagreement between the reviewers was resolved by a third investigator. We used the Newcastle-Ottawa Scale (NOS) to assess the quality of each study. 12 The Newcastle-Ottawa scale evaluated three components: selection of the cohort, comparability of cohorts on the basis of the design or analysis, how the exposure was ascertained and how outcomes of interest were assessed. Studies achieving six or more stars were considered to be of high quality.
| Statistical analysis
The main outcome of the meta-analysis was to evaluate the differences in NLR values between healthy subjects, patients with stable COPD and those with acute exacerbation. To this regard, standardized mean differences (SMD), and 95% confidence intervals (CIs), were used to construct forest plots of continuous data. P < 0.05 was considered statistically significant. In one study 13 the mean and standard deviation were estimated from the median and range.
14 Heterogeneity of SMD across studies was tested by using the Q statistic (significance level at P < 0.10). The I 2 statistic, a quantitative measure of inconsistency across studies, was also calculated (I 2 < 25%, no heterogeneity; I 2 between 25% and 50%, moderate heterogeneity; I 2 between 50% and 75%, large heterogeneity; and I 2 > 75%, extreme heterogeneity). 15, 16 Due to the elevated heterogeneity, a random-effects model was used to calculate the pooled SMD and corresponding 95% confidence intervals.
To evaluate the presence of potential publication bias, the association between study size and magnitude of effect were analysed by means of Begg's adjusted rank correlation test and Egger's regression asymmetry test at the P < 0.05 level of significance. 17 Sensitivity analysis was conducted to investigate the influence of an individual study on overall risk estimate, by sequentially excluding one study in each step. 18 The Duval and Tweedie "trim and fill" procedure was also performed 19 to further assess the possible effect of publication bias. This method considers the possibility of hypothetical "missing" studies that might exist and recalculates a pooled SMD that incorporates the hypothetical missing studies as though they actually existed. Statistical analyses were performed using MedCalc for Windows, version 15.4 64 bit (MedCalc Software, Ostend, Belgium) and StatsDirect 3.1.8 (StatsDirect Ltd, Altrincham, UK) and Stata 14 (STATA Corp., College Station, TX, USA). Our study is fully compliant with the PRISMA statement regarding the reporting of systematic reviews and meta-analyses and the broader EQUATOR guidelines. 20 
| RESULTS
A flow chart describing the study selection is presented in Figure 1 . We initially retrieved 247 studies. Of these, 206 were excluded after initial screening. After full-text review of the remaining 21 articles, twelve studies were excluded because they did not meet the inclusion criteria. [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] Nine studies were included in the final analysis.
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| NLR in stable COPD vs controls
The characteristics of the seven studies investigating the NLR in COPD vs controls are presented in Table 1 . These studies, mainly retrospective, comprised a total of 775 COPD patients (591 males and 184 females, mean age 62 ± 10 years) and 496 healthy controls (378 males and 118 females, mean age 59 ± 10 years). 13, 33, [36] [37] [38] [39] [40] The mean NLR value was 1.79 ± 0.84 and 2.58 ± 1.87 in COPD patients and healthy controls, respectively, indicating a 44% increase in COPD patients. The forest plot showed higher mean NLR values in COPD patients, when compared to controls, in all the studies (Figure 2) . Because of the substantial heterogeneity between studies (I 2 = 87.7%, P < 0.001), randomeffects models were used. Pooled results showed that NLR values were significantly higher in patients with COPD (SMD 0.773, 95% CI 0.410-1.136; P < 0.001).
Results stability was evaluated through sensitivity analysis ( Figure 3) . The corresponding pooled SMD values were not substantially altered when single studies were removed, suggesting that the results of the meta-analysis were stable. A trend towards publication bias was observed (Begg, P = 0.38; Egger, P = 0.09). When the trim-and-fill method was used to correct the result, four potential missing studies were required in the left side of the funnel plot to ensure symmetry ( Figure 4 ). The adjusted SMD was reduced (0.361 μmol/L, 95% CI −0.023-0.745 μmol/L, P = 0.066).
| NLR in stable COPD vs AECOPD
The characteristics of the six studies investigating NLR values in AECOPD vs stable COPD are presented in Table 2 . Four studies were retrospective 32, 34, 37, 39 whereas the remaining two were prospective. 34, 39 They comprised a total of 527 AECOPD patients (411 males and 116 females, mean age 64 ± 10 years) and 620 stable COPD (480 males and 140 females, mean age 61 ± 10 years). The mean NLR value was 2.62 ± 2.26 and 6.38 ± 5.80 in COPD and AECOPD patients respectively, indicating a 144% increase in AECOPD patients. The forest plot showed higher mean NLR values in AECOPD, when compared to patients with stable COPD, in all studies. There was a significant heterogeneity between studies (I 2 = 80.8%, P < 0.001, Figure 5 ).
Pooled results showed that NLR values were significantly higher in patients with AECOPD (random effects SMD 0.850, 95% CI 0.549-1.151; P < 0.001). Sensitivity Mean and standard deviation (SD) were estimated from formulas using the median and range as described by Hozo et al. 14 .
AECOPD, acute exacerbation chronic obstructive pulmonary disease; COPD, chronic obstructive pulmonary disease; NLR, neutrophil to lymphocyte ratio; NOS, Newcastle-Ottawa quality assessment scale for case-control studies.
analysis indicated that pooled SMD values were not substantially altered when single studies were removed, suggesting that the results of the meta-analysis were stable ( Figure 6 ). No evidence of publication bias was noted (Begg, P = 0.27; Egger, P = 0.13). Trim-and-fill analysis showed two potential missing studies in the left side of the funnel plot to ensure symmetry ( Figure 7 ). The adjusted SMD was slightly reduced, but remained highly significant (0.630 μmol/L, 95% CI 0.302-0.958 μmol/L, P < 0.0001).
| DISCUSSION
Neutrophil to lymphocyte ratio (NLR) is a widely available, easy to determine, and relatively inexpensive index which has been extensively studied in recent years as a predictor of disease development, progression, response to medications and prognosis. It is well established that NLR values are increased in several malignancies, when compared to patients with benign tumours or healthy individuals, and correlate well with cancer stage and survival.
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F I G U R E 2 Forest Plot of Studies
Examining NLR and COPD. Cochran's Q = 48.8 (df = 6), P < 0.0001; I Similarly, NLR values have been shown to correlate with disease activity and outcomes in several chronic inflammatory disease states, such as arthritis, hypertension, diabetes and inflammatory bowel disease. Vaguliene et al. examined the white blood cell count and the NLR in four study groups: patients with lung cancer, lung cancer and COPD, COPD alone, and healthy controls. 13 Although there were no significant between-group differences in the lymphocyte population, patients with cancer had higher NLR values than those with COPD who, in turn, had higher NLR values than healthy controls. This suggests that cancer and COPD are both characterized by an inflammatory state that primarily involves the neutrophils, but not lymphocytes. The roles of the neutrophils in the pathogenesis of COPD are only partially known. Neutrophils can release consistent amounts of reactive oxygen species (ROS) which can further enhance the inflammation cascade through AECOPD, acute exacerbation chronic obstructive pulmonary disease; COPD, chronic obstructive pulmonary disease; NLR, neutrophil to lymphocyte ratio; NOS, Newcastle-Ottawa quality assessment scale for case-control studies.
activation of mitogen-activated protein kinases (MAPK) and redox-sensitive transcription factors, such as nuclear factor kappa B (NF-kB) and activator-protein 1 (AP-1). 41 Furthermore, activated neutrophils produce other essential inflammatory mediators, such as proteases (neutrophil elastase, cathepsin G, proteinase-3), matrix metalloproteinases (MMP-8, MMP-9), and myeloperoxidase (MPO). 42, 43 The imbalance between proteases and their inhibitors cause parenchymal destruction and emphysematous changes, while the production of cytokines, enzymes, adhesion molecules and growth factors from activated neutrophils promote infiltration of the airways by inflammatory cells and further production of proinflammatory factors, creating a vicious circle which maintains and enhances the local and systemic effects of the disease. 44 Neutrophils have also an important role in AECOPD. The most common causes of AECOPD are viral and bacterial infections, which stimulate the production of proinflammatory and chemotactic factors (IL-6, IL-8, CXCL5, CXCL8 and TLB4) which, in turn, cause neutrophil recruitment and acute inflammation. 45 An increase in neutrophils has been observed in airway secretions and bronchial The influence of individual studies on the overall standardized mean difference is shown. AECOPD, acute exacerbation chronic obstructive pulmonary disease; NLR, neutrophil to lymphocyte ratio biopsy specimens during COPD exacerbations. Furthermore, their percentage in the distal airspace has a negative linear relationship with the FEV1/FVC ratio. 46 Air pollution is another frequent trigger of AECOPD; studies have shown that exposure of healthy volunteers to diesel exhaust particles results in increased number of neutrophils through the production of proinflammatory cytokines, such as granulocyte-macrophage colony-stimulating factor (GM-CSF) and IL-8. 47, 48 Nevertheless, the number or percentage of neutrophils alone is not a reliable index of AECOPD onset and severity, as opposed to the NLR. In this meta-analysis, we observed that (a) NLR values were significantly higher in patients with stable COPD when compared to healthy subjects, though the difference (+44%) is not large enough to allow clear discrimination; and (b) NLR values were significantly higher in AECOPD patients when compared to patients with stable disease. Further studies, in larger cohorts, are needed to determine whether the NLR is useful to discriminate between COPD patients with stable disease, those with acute exacerbations, and subjects without the disease. However, the magnitude of the differences in NLR values between stable COPD and AECOPD observed in our study (+144% in AECOPD) suggests that this tool might be particularly useful for the identification of patients with AECOPD.
The significant heterogeneity in the eligible studies, despite using robust criteria such as a COPD diagnosis based on the GOLD criteria and a case-control design, might be secondary to the retrospective design of most studies, the lack of information about comorbidities which may impact the inflammatory state of the disease, and the variability of the clinical presentation of patients diagnosed with the GOLD criteria. Furthermore, the presence of peripheral blood eosinophilia and the use of corticosteroids have been shown to influence white blood cell populations and, as a consequence, the NLR. [21] [22] [23] For this reason, we used random-effects models to ensure the stability of the meta-analysis results. However, future prospective and appropriately controlled studies will likely allow more robust evaluation of the clinical usefulness of the NLR in stable and exacerbated COPD.
In conclusion, our results demonstrate that blood NLR values are significantly higher in patients with stable COPD in comparison to healthy controls, however, the magnitude of the reported difference was reduced after trim and fill adjustment. Furthermore, blood NLR values are significantly higher in patients with acute COPD exacerbation than in those with stable COPD, and this difference was not significantly affected by the trim and fill. Pending the results of larger prospective studies that also investigate specific cut-off values, these findings suggest a potential clinical use of NLR in COPD.
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Investigating Patients with COPD and AECOPD After Trimming and Filling. Dummy studies and genuine studies are represented by enclosed circles and free circles, respectively. AECOPD, acute exacerbation chronic obstructive pulmonary disease; COPD, chronic obstructive pulmonary disease
